Immune Repertoire Sequencing Market Players:
- Agilent Technologies, Inc
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Illumina, Inc.
- Pacific Biosciences of California, Inc
- QIAGEN N.V.
- Thermo Fisher Scientific, Inc.
- F. Hoffmann-La Roche AG
- Takara Bio, Inc
- Oxford Nanopore Technologies, Ltd
- BGI Group
- Atreca Inc
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of immune repertoire sequencing is estimated at USD 397.74 million.
The global immune repertoire sequencing market size was around USD 366.11 million in 2025 and is likely to expand at a CAGR of more than 9.6%, surpassing USD 915.62 million revenue by 2035.
North America immune repertoire sequencing market will hold around 40.8% share by 2035, driven by high healthcare spending and strong demand for immunotherapy.
Key players in the market include Agilent Technologies, Inc, Illumina, Inc., Pacific Biosciences of California, Inc, QIAGEN N.V., Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche AG, Takara Bio, Inc, Oxford Nanopore Technologies, Ltd, BGI Group, Atreca Inc.
